| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 05/07/2003 | CN1416343A Skin whiteners contg. hydroxytetronic acid |
| 05/07/2003 | CN1416340A Compsns for delivery of contisol antagonist |
| 05/07/2003 | CN1416339A IL-8 receptor antagonsts |
| 05/07/2003 | CN1415376A Compound preparation of Chinese traditional medicine for curing chronic fatigue syndrome and its preparation method |
| 05/07/2003 | CN1415365A Chinese medical preparation for preventing and curing blaze of shrimps corpus hemorrhagicum, gill rot and pond syndrome |
| 05/07/2003 | CN1415351A Usage and preparation of smoke tree produced in Qinling Mountains |
| 05/07/2003 | CN1415312A Application of preparing health products of anti-anoxia made from concentrated powder of non-denatured lactalbumin |
| 05/07/2003 | CN1415309A Nano selenium of Melatonin and its preparation method |
| 05/07/2003 | CN1107677C Camptothecin derivatives and use thereof as antimutor agents |
| 05/07/2003 | CN1107505C Synergistic combination of AIDS antiviral compounds and HIV inhibitor |
| 05/07/2003 | CN1107499C Nitric oxide donor compsns. and method for treating anal disorders |
| 05/06/2003 | USRE38115 Treating chronic or intractable pain, for treating tinnitus and for treating sexual dysfunction |
| 05/06/2003 | US6559312 Intermediates useful for the preparation of antihistaminic piperidine derivatives |
| 05/06/2003 | US6559303 Bridgehead atoms are bonded to one or more bridges that interconnect one or more ring systems thereby forming a large cyclic structure. Located in each bridge are two or more nitrogenous moieties that are derivatized with chemical |
| 05/06/2003 | US6559293 Topiramate sodium trihydrate |
| 05/06/2003 | US6559282 Induction of antibodies against leutenizing hormone releasing hormone in mammals; obtain mammal, administer modulator, monitor immune response, evaluate for prevention of infections |
| 05/06/2003 | US6559185 Nitromethyl ketone compounds having aldose reduction inhibiting properties and methods for their use |
| 05/06/2003 | US6559179 Tinvention relates to the use of compounds as inhibitors of the fatty acid synthase FabH. |
| 05/06/2003 | US6559176 A method for regulating the activity of an autoinducer-2 receptor comprising contacting an autoinducer-2 receptor with an AI-2 agonist or antagonist compound. |
| 05/06/2003 | US6559171 Muscarinic receptor modulators 7-oxo-2-azabicyclo(2.2.1)heptanes of formula (I) which are useful for the treatment of various diseases and conditions, for example, Alzheimer's disease, glaucoma, psychosis, |
| 05/06/2003 | US6559168 Thiazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes |
| 05/06/2003 | US6559167 Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable arylsulfonyl or heteroarylsulfonyl group attached to the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under |
| 05/06/2003 | US6559166 A class of phenylsulphonyl derivatives wherein the sulphonyl moiety is also attached to an N-arylalkyl-substituted azetidine, pyrrolidine or piperidine ring are selective antagonists of the human 5-HT2A receptor and are therefore |
| 05/06/2003 | US6559165 Prevention, treatment, or management of apnea, apnea disorders, bulimia nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythmia, syncope, other disorders, or symptoms thereof using (-) norcisapride, or salt |
| 05/06/2003 | US6559163 Agonists, antagonists or inverse agonists for GABAA brain receptors; useful in diagnosis and treatment of anxiety, depression |
| 05/06/2003 | US6559160 These compounds and compositions bind to the CXCR3 chemokine receptor and are useful for treating diseases and conditions responsive to the modulation of CXCR3 activity, such as multiple sclerosis, rheumatoid arthritis, psoriasis, cancer, |
| 05/06/2003 | US6559159 Kappa opioid receptor ligands |
| 05/06/2003 | US6559155 Pyrimidinone derivatives for the treatment of atherosclerosis |
| 05/06/2003 | US6559154 Composition of sodium channel blocking compound |
| 05/06/2003 | US6559153 1-(4-(((4-Amino-6,7-dimethoxy-quinazolin-2-yl)-methyl-amino) methyl)-4-phenyl-piperidin-1-yl)-1-cyclopropyl-methanone; treating disease states ameliorated by blockade of alpha-1 adrenoceptors; sleep/psychological disorders |
| 05/06/2003 | US6559152 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
| 05/06/2003 | US6559147 3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4 -(2,3 -dihydroxypropoxy)pyridin-2-yl)oxy)-4-hydroxybenzamidine, for example |
| 05/06/2003 | US6559146 Neuroprotective effects by inducing calbindin D28Kd, one of Ca2+-binding proteins |
| 05/06/2003 | US6559142 Tricyclic substituted cyclic sulfonamides compound is useful for treating heart disease, multiple sclerosis, arthritis, atherosclerosis, and osteoporosis |
| 05/06/2003 | US6559139 Combination chemotherapy |
| 05/06/2003 | US6559137 Characterized by favorable aqueous solubility, high oral bioavailability and facile in vivo generation of the active ingredient |
| 05/06/2003 | US6559131 Fucan increases the expression and/or the activity of a fibroblastic metalloproteinase or that inhibits leukocyte elastase, or both for treating a periodontal pathology or a dermal pathology |
| 05/06/2003 | US6558952 Expansion of preferential pancreatic cells; generate nutrient broth, inoculate with pancreatic cells and gastrin receptor ligand, monitor propagation of pancreatic cells |
| 05/06/2003 | US6558950 Nucleotide sequences coding polypeptide for use in the treatment of programed cell death defects |
| 05/06/2003 | US6558925 Stem cell inhibitor |
| 05/06/2003 | US6558918 Nucleic acid that encode a cell growth regulatory protein |
| 05/06/2003 | US6558707 Micronized particles in carrier such as a purified, micro-crystalline or alkylated cellulose |
| 05/06/2003 | US6558692 Over-coated chewing gum formulations |
| 05/06/2003 | US6558661 Inhibiting binding of interferon-gamma to its native receptor |
| 05/06/2003 | US6558657 Synthetic polymer, carbohydrate or protein substituted with disulfide moiety that inhibits fat hydrolysis |
| 05/06/2003 | CA2244194C Dihydrobenzofuran and related compounds useful as anti-inflammatory agents |
| 05/06/2003 | CA2126691C Gapped 2' modified oligonucleotides |
| 05/06/2003 | CA2082160C Humanised and chimeric monoclonal antibodies |
| 05/02/2003 | EP1306436A1 P53-dependent novel apoptosis-associated protein and method of screening apoptosis controlling agent |
| 05/02/2003 | EP1306431A1 Tumor antigen |
| 05/02/2003 | EP1306377A2 Pyridyl-oxazoles and their use as cytokines inhibitors |
| 05/02/2003 | EP1306376A1 Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist |
| 05/02/2003 | EP1306368A2 3,4-dihydro-1H-naphtalene derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 05/02/2003 | EP1306367A1 Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products |
| 05/02/2003 | EP1306094A1 Preventives or remedies for obesity or fatty liver |
| 05/02/2003 | EP1306093A1 Nerve regeneration promoters containing semaphorin inhibitor as the active ingredient |
| 05/02/2003 | EP1306091A2 Stimulation of beta cell proliferation |
| 05/02/2003 | EP1306090A1 Cosmetics or dermatological preparations containing polymers having phosphorylcholine side chain |
| 05/02/2003 | EP1305635A2 Methods to identify compounds that modulate rage |
| 05/02/2003 | EP1305434A2 A human disintegrin protein |
| 05/02/2003 | EP1305425A2 Drug metabolizing enzymes |
| 05/02/2003 | EP1305418A2 Human monoclonal antibody against hepatitis c virus e2 glycoprotein |
| 05/02/2003 | EP1305414A2 Modified cea and uses thereof |
| 05/02/2003 | EP1305404A2 Protein phosphatases |
| 05/02/2003 | EP1305342A2 Human kininogen d5 domain polypeptides and their use |
| 05/02/2003 | EP1305340A2 Sequences for integrin alpha-8 |
| 05/02/2003 | EP1305330A1 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents |
| 05/02/2003 | EP1305329A1 6.alpha.,9.alpha.-difluoro-17.alpha.-[(2-furanylcarboxyl)oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent |
| 05/02/2003 | EP1305319A1 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists |
| 05/02/2003 | EP1305316A2 Azabicyclic derivatives and their therapeutic use |
| 05/02/2003 | EP1305314A1 Crystalline therapeutic agent |
| 05/02/2003 | EP1305313A1 Fused heterocyclic derivatives as phosphodiesterase inhibitors |
| 05/02/2003 | EP1305309A1 Lactam inhibitors of factor xa which are useful for the treatment of thrombosis |
| 05/02/2003 | EP1305307A1 Indole derivatives useful for the treatment of cns disorders |
| 05/02/2003 | EP1305306A2 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission |
| 05/02/2003 | EP1305303A1 NOVEL FORM OF (R)- i N /i - 5-METHYL-8-(4-METHYLPIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-2-NAPHTHYL]-4-MORPHOLINOBENZAMIDE |
| 05/02/2003 | EP1305301A1 Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators |
| 05/02/2003 | EP1305299A1 Cyclic polyamine compounds for cancer therapy |
| 05/02/2003 | EP1305295A1 Imidazole derivatives |
| 05/02/2003 | EP1305294A2 Imidazolyl derivatives |
| 05/02/2003 | EP1305293A1 Hexahydro-7-imino-1h-azepin-2-yl-hexanoic acid derivatives as inhibitors of inducible nitric oxide synthase |
| 05/02/2003 | EP1305291A1 3-substituted isoquinolin-1-yl derivatives |
| 05/02/2003 | EP1305051A2 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer |
| 05/02/2003 | EP1305045A1 Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
| 05/02/2003 | EP1305036A2 Nutritional composition |
| 05/02/2003 | EP1305027A2 Use of an aldehyde 5-oxo-1,2,4-triazine hydrazide for the treatment of cancer |
| 05/02/2003 | EP1305026A2 Barbituric acid analogs as therapeutic agents |
| 05/02/2003 | EP1305023A1 Use of selective adenosine a1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis |
| 05/02/2003 | EP1305021A1 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| 05/02/2003 | EP1305015A1 Substituted styryl benzylsulfones for treating proliferative disorders |
| 05/02/2003 | EP1305007A2 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| 05/02/2003 | EP1304921A2 Transgenic mice containing targeted gene disruptions |
| 05/02/2003 | EP1223966B1 Use of gdnf for treating corneal defects |
| 05/02/2003 | EP1221939A4 Ortho ester lipids |
| 05/02/2003 | EP1200064B1 Delivery system for oral care compositions comprising organosiloxane reins using a removable backing strip |
| 05/02/2003 | EP1196167A4 Method of reducing neuronal injury or apoptosis |
| 05/02/2003 | EP1189611A4 Cancer therapy |
| 05/02/2003 | EP1185516B1 Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting effect |
| 05/02/2003 | EP1121351A4 Preparation of (s)-2-amino-6,6-dimethoxyhexanoic acid methyl ester via novel dioxolanes |
| 05/02/2003 | EP1119351B1 Use of catechol derivatives as proteinase inhibitors |